Çí»ç¸Þµò¾×(Ŭ·Î¸£Çí½Ãµò±Û·çÄܻ꿰¾×) 100mL Hexamedine Sol.
ÀϹÝÀǾàǰ | »èÁ¦
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
ÀϹÝ
¹«»ö Åõ¸íÇÑ ¾×Á¦·Î¼ ¹æÇ⼺À» Áö´Ï°í ÀÖ´Ù
Á¦Á¶È¸»ç
ºÎ±¤¾àǰ(ÁÖ)
ÆÇ¸Åȸ»ç
ºÎ±¤¾àǰ(ÁÖ)
Çã°¡Á¤º¸
ÃëÇÏ
(2024.01.30)
BIT ¾àÈ¿ºÐ·ù
±¸³»¿°, ±¸°»ì±Õ¼Òµ¶Á¦
º¹ÁöºÎºÐ·ù
231[Ä¡°ú±¸°¿ë¾à ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
642202401 \0 ¿ø/100mL/º´(2024.09.01) (ÇöÀç¾à°¡) \898 ¿ø/100mL/º´(2017.11.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
chlorhexidine / R02AA05
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
°æÈÇǸ¶ÀÚÀ¯Æú¸®¿Á½Ç40 ,
°æÈÇǸ¶ÀÚÀ¯Æú¸®¿Á½Ç40 ,
³ó±Û¸®¼¼¸° ,
³ó±Û¸®¼¼¸° ,
¿¡Åº¿Ã ,
¿¡Åº¿Ã ,
Á¤Á¦¼ö ,
Á¤Á¦¼ö ,
Á¤ÇâÀ¯Á¶ÇÕÇâ ,
Á¤ÇâÀ¯Á¶ÇÕÇâ ,
È¿¼Ò󸮽ºÅ׺ñ¾Æ ,
È¿¼Ò󸮽ºÅ׺ñ¾Æ
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
642202401
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/100mL/º´(2024.09.01) (ÇöÀç¾à°¡)
\898 ¿ø/100mL/º´(2017.11.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
¹«»ö Åõ¸íÇÑ ¾×Á¦·Î¼ ¹æÇ⼺À» Áö´Ï°í ÀÖ´Ù
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
100mL
ÁÖ¼ººÐÄÚµå
131330CLQ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806422024004
º¸°ü¹æ¹ý
Â÷±¤±â¹Ð¿ë±â, »ó¿Âº¸Á¸
¾à¸®ÀÛ¿ë
[Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
1. ÁÖÈ¿´É È¿°ú
´ÙÀ½ Áúȯ¿¡ ÀÇÇÑ ¿°ÁõÀÇ ¿ÏÈ :
º¸Ã¶(ÀÇÄ¡)¿¡ ÀÇÇÑ ¿°Áõ, ¾Æ±¸Ã¢ µîÀÇ ±¸°³» ĵð´Ù°¨¿°Áõ, Ä¡Àº¿°, Àεο°, ¾ÆÇÁŸ¼º ±¸³»¿°
2. ´ÙÀ½ Áúȯ¿¡µµ »ç¿ëÇÒ ¼ö ÀÖ´Ù.
Ä¡±Ù¸· ¼ö¼úÈÄ »ì±Õ¼Òµ¶
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ȸ 15mL 1ÀÏ 2ȸ ¾à 1ºÐµ¿¾È ¾çÄ¡ÁúÇϸç, ÀÇÄ¡·Î ÀÎÇÑ ±¸³»¿°ÀÇ °æ¿ì¿¡´Â ÀÇÄ¡¸¦ 1ÀÏ 2ȸ 15ºÐ°£ ´ã°¡ ¼¼Ã´ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
°æ°í
±¸°³» Á¤»ó ¼¼±ÕÃÑÀÇ ºÒ±ÕÇüÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î Àå±â°£ Åõ¿©ÇÏÁö ¾Ê´Â´Ù.
±Ý±â
ÀÌ ¾à¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
½ÅÁßÅõ¿©
õ½Ä µî ¾Ë·¹¸£±â ÁúȯÀÌ Àְųª, ÀÌ·¯ÇÑ º´·Â ¶Ç´Â °¡Á··ÂÀÌ Àִ ȯÀÚ
ÀÌ»ó¹ÝÀÀ
1) ±¸°
Ä¡¾Æ³ª ±¸°Ç¥¸é¿¡ Âø»ö Áõ°¡, Ä¡Àº¿¬»óÄ¡¼® Çü¼º Áõ°¡, ¹Ì°¨°¢ÀÇ º¯È µîÀÌ ³ªÅ¸³µ´Ù. ƯÈ÷ ¼Ò¾Æ¿¡¼ ±¸°Á¡¸·ÀÇ Ç¥ÇÇÅ»¶ô, °æ¹ÌÇÑ ÀÚ±ØÀÌ º¸°íµÈ ¹Ù ÀÖ´Ù.
2) ¼ï
µå¹°°Ô ¼ïÁõ»óÀÌ ÀϾ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ°í ±¸¿ª, ºÒÄè°¨, ½ÄÀº ¶¡, ¾îÁö·¯¿ò, ´ä´äÇÔ, È£Èí°ï¶õ, ¹ßÀÛ µîÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Áï½Ã Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
3) °ú¹ÎÁõ
¶§¶§·Î ¹ßÁø, µÎµå·¯±â µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
4) ±âŸ
Ŭ·Î¸£Çí½Ãµò ÇÔÀ¯ ±¸°¼¼Ã´Á¦Á¦¿¡¼ ÀϽÃÀûÀÎ ÀÌÇϼ±¿°ÀÌ º¸°íµÈ ¹Ù ÀÖ´Ù.
ÀϹÝÀû ÁÖÀÇ
1) ÀϹÝÀûÀÎ ¼¼±Õ°¨¿°½Ã¿¡´Â Ç×»ý¹°ÁúÀ» Åõ¿©ÇÏ¿©¾ß ÇÑ´Ù.
2) Ä¡·á´Â º¸Åë 10ÀÏÀ» ³ÑÁö ¾Ê´Â´Ù.
3) Ä¡Àº¿°°ú Ä¡ÁÖ¸·¿°ÀÌ ÇÕº´µÈ ȯÀÚ¸¦ ÀÌ ¾àÀ¸·Î Ä¡·áÇÑ ÈÄ, Ä¡Àº¿°ÀÇ À¯¹«´Â Ä¡ÁÖ¸·¿° Ä¡·áÀÇ Áß¿äÇÑ ÆÇÁ¤±âÁØÀ¸·Î ÀÌ¿ëµÇ¼´Â ¾ÈµÈ´Ù.
4) Ä¡¾ÆÇ¥¸é, º¸Ã¶¹°, ÇôÀÇ µÞ¸é°ú °°Àº ±¸°Ç¥¸é¿¡ Âø»öÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
5) °ÅÄ£ Ç¥¸éÀ̳ª Æ´ÀÌ ÀÖ´Â ¾È¸éÁ¤¹æÀÇ º¸Ã¶¹°À» Âø¿ëÇÑ È¯ÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇØ¾ß ÇÑ´Ù. Ä¡°úÀûÀÎ ¿¹¹æ¿¡ ÀÇÇØ Âø»öÀÌ Á¦°ÅµÇ±â ¾î·Æ°í, µå¹°°Ô º¸Ã¶¹°À» ¹Ù²ã¾ß ÇÒ °æ¿ì°¡ ÀÖÀ¸¹Ç·Î Âø»öµÇ´Â °ÍÀ» ¿øÇÏÁö ¾Ê´Â ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¸»¾Æ¾ß ÇÑ´Ù.
ÀӺο¡ ´ëÇÑ Åõ¿©
[ÀӺαݱ⠼ººÐ Á¶È¸]
ÀӺο¡´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÏ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù.
¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿©
¸ðÀ¯·Î ÀÌ ¾à¹°ÀÌ ÀÌÇàµÇ´ÂÁö´Â ¾Ë·ÁÁöÁö ¾Ê¾ÒÀ¸³ª, ¸¹Àº ¾à¹°ÀÌ ¸ðÀ¯·Î ºÐºñµÇ¹Ç·Î ¼öÀ¯ºÎ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿©
¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿©
18¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ¿¡ ´ëÇÑ À¯È¿¼º ¹× ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù.
Àû¿ë»óÀÇ ÁÖÀÇ
ÇÔ¼ö¿ëÀ¸·Î¸¸ »ç¿ëÇϰí, ³»º¹¿ëÀ¸·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù.
º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ
1) ¼Ò¾ÆÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù.
2) Á÷»çÀϱ¤À» ÇÇÇÏ°í µÇµµ·ÏÀÌ¸é ½À±â°¡ ÀûÀº ¼´ÃÇÑ °÷¿¡ ¹ÐÀüÇÏ¿© º¸°üÇÑ´Ù.
3) ȱ⿡ °¡±îÀÌ µÎÁö ¾Ê´Â´Ù.
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Bµî±Þ
(Chlorhexidine gluconate °¡±Û¾× )
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
º¹¾à¶óº§
À̹ÌÁö
º¹¾à¼³¸í
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù.
*
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù.
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Chlorhexidine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Chlorhexidine's antimicrobial effects are associated with the attractions between chlorhexidine (cation) and negatively charged bacterial cells. After chlorhexidine is absorpted onto the organism's cell wall, it disrupts the integrity of the cell membrane and causes the leakage of intracellular components of the organisms.
Pharmacology
Chlorhexidine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Chlorhexidine, a topical antimicrobial agent, is bactericidal. Because of its positive charge, the chlorhexidine molecule reacts with the microbial cell surface to destroy the integrity of the cell membrane. This novel mechanism of action makes it highly unlikely for the development of bacterial resistance.
Metabolism
Chlorhexidine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
Protein Binding
Chlorhexidine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 87%
Half-life
Chlorhexidine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
Absorption
Chlorhexidine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorption of chlorhexidine from the gastrointestinal tract is very poor. Additionally, an in vivo study in 18 adult patients found no detectable plasma or urine chlorhexidine concentrations following insertion of four periodontal implants under clinical conditions.
Toxicity
Chlorhexidine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 = 2g/kg (human, oral); LD50 = 3 g/kg (rat, oral); LD50 = 2.5 g/kg (mice, oral); LD50 = 21 mg/kg (male rat, IV); LD50 = 23 mg/kg (female rat, IV); LD50 = 25 mg/kg (male mice, IV); LD50 = 24 mg/kg (female mice, IV); LD50 = 1g/kg (rat, subcutaneous); LD50 = 637 mg/kg (male mice, subcutaneous); LD50 = 632 mg/kg (female mice, subcutaneous)
Drug Interactions
Chlorhexidine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Description
Chlorhexidine¿¡ ´ëÇÑ Description Á¤º¸ A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque. [PubChem]
Drug Category
Chlorhexidine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial AgentsAnti-Infective Agents, LocalAnti-InfectivesDisinfectantsMouthwashes
Smiles String Canonical
Chlorhexidine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(NC1=CC=C(Cl)C=C1)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1
Smiles String Isomeric
Chlorhexidine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N\C(NC1=CC=C(Cl)C=C1)=N/C(N)=N/CCCCCC\N=C(N)\N=C(/N)NC1=CC=C(Cl)C=C1
InChI Identifier
Chlorhexidine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)/f/h31-32H,25-28H2/b29-19+,30-20+,33-21+,34-22+
Chemical IUPAC Name
Chlorhexidine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1E)-2-[6-[[amino-[[amino-[(4-chlorophenyl)amino]methylidene]amino]methylidene]amino]hexyl]-1-[amino-[(4-chlorophenyl)amino]methylidene]guanidine
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ